A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

NCT01073293 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1054

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillomavirus Infections

Interventions

BIOLOGICAL: V503 Vaccine
BIOLOGICAL: REPEVAX™ (Concomitant)
BIOLOGICAL: REPEVAX™ (Non-concomitant)

Sponsor

Merck Sharp & Dohme LLC